LIGORIO, FRANCESCA
LIGORIO, FRANCESCA
Universita' degli Studi di MILANO
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
2024 C. Vernieri, F. Ligorio, D. Tripathy, V.D. Longo
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
2023 E. Zattarin, L. Mariani, A. Menichetti, R. Leporati, L. Provenzano, F. Ligorio, G. Fucà, R. Lobefaro, L. Lalli, A. Vingiani, F. Nichetti, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, C. Corti, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, D. Presti, C. Sposetti, C.A. Giorgi, V. Guarneri, R. Pedersini, A. Losurdo, D. Generali, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial
2022 F. Ligorio, G. Fucà, L. Provenzano, R. Lobefaro, L. Zanenga, A. Vingiani, A. Belfiore, A. Lorenzoni, A. Alessi, G. Pruneri, F. de Braud, C. Vernieri
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
2022 C. Vernieri, G. Fucà, F. Ligorio, V. Huber, A. Vingiani, F. Iannelli, A. Raimondi, D. Rinchai, G. Frigè, A. Belfiore, L. Lalli, C. Chiodoni, V. Cancila, F. Zanardi, A. Ajazi, S. Cortellino, V. Vallacchi, P. Squarcina, A. Cova, S. Pesce, P. Frati, R. Mall, P.A. Corsetto, A.M. Rizzo, C. Ferraris, S. Folli, M.C. Garassino, G. Capri, G. Bianchi, M.P. Colombo, S. Minucci, M. Foiani, V.D. Longo, G. Apolone, V. Torri, G. Pruneri, D. Bedognetti, L. Rivoltini, F. de Braud
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
2022 E. Zattarin, F. Nichetti, F. Ligorio, L. Mazzeo, R. Lobefaro, G. Fuca, G. Peverelli, A. Vingiani, G. Bianchi, V, G. Capri, F. de Braud, C. Vernieri
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
2022 F. Ligorio, S. Di Cosimo, P. Verderio, C.M. Ciniselli, S. Pizzamiglio, L. Castagnoli, M. Dugo, B. Galbardi, R. Salgado, S. Loi, S. Michiels, T. Triulzi, E. Tagliabue, S. El-Abed, M. Izquierdo, E. de Azambuja, P. Nuciforo, J. Huober, L. Moscetti, W. Janni, M.A. Coccia-Portugal, P.A. Corsetto, A. Belfiore, D. Lorenzini, M.G. Daidone, A. Vingiani, L. Gianni, S.M. Pupa, G. Bianchini, G. Pruneri, C. Vernieri
Impact of pathological stratification on the clinical outcomes of advanced well‐differentiated/dedifferentiated liposarcoma treated with trabectedin
2021 C. Fabbroni, G. Fuca, F. Ligorio, E. Fumagalli, M. Barisella, P. Collini, C. Morosi, A. Gronchi, A.P.D. Tos, P.G. Casali, R. Sanfilippo
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
2021 F. Ligorio, I. Pellegrini, L. Castagnoli, A. Vingiani, R. Lobefaro, E. Zattarin, M. Santamaria, S.M. Pupa, G. Pruneri, F. de Braud, C. Vernieri
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab
2021 F. Ligorio, G. Fuca, E. Zattarin, R. Lobefaro, L. Zambelli, R. Leporati, C. Rea, G. Mariani, G.V. Bianchi, G. Capri, F. de Braud, C. Vernieri
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
Prolonged benefit from palbociclib plus letrozole in heavily pretreated advanced male breast cancer: case report
2021 E. Zattarin, F. Ligorio, F. Nichetti, G. Bianchi, G. Capri, F. de Braud
HER2 signaling and breast cancer stem cells: the bridge behind HER2-positive breast cancer aggressiveness and therapy refractoriness
2021 S.M. Pupa, F. Ligorio, V. Cancila, A. Franceschini, C. Tripodo, C. Vernieri, L. Castagnoli
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
2020 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
2020 C. Vernieri, M. Prisciandaro, F. Nichetti, R. Lobefaro, G. Peverelli, F. Ligorio, E. Zattarin, M.S. Cona, P. Sepe, F. Corti, S. Manglaviti, M. Brambilla, B. Re, A. Belfiore, G. Pruneri, L. Celio, G. Mariani, G.V. Bianchi, L. Rivoltini, G. Capri, F. de Braud
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
2020 E. Zattarin, R. Leporati, F. Ligorio, R. Lobefaro, A. Vingiani, G. Pruneri, C. Vernieri
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
2020 E. Zattarin, C. Fabbroni, F. Ligorio, A. Marra, C. Corti, O. Bernocchi, M. Sirico, D. Generali, G. Curigliano, G. Bianchi, G. Capri, L. Rivoltini, F. De Braud, C. Vernieri
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
2020 C. Vernieri, F. Corti, F. Nichetti, F. Ligorio, S. Manglaviti, E. Zattarin, C.G. Rea, G. Capri, G.V. Bianchi, F. de Braud
Fasting-mimicking diet plus chemotherapy in breast cancer treatment
2020 C. Vernieri, F. Ligorio, E. Zattarin, L. Rivoltini, F. de Braud
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis
2020 R. Lobefaro, E. Zattarin, F. Nichetti, M. Prisciandaro, F. Ligorio, M. Brambilla, P. Sepe, F. Corti, G. Peverelli, A. Ottini, T. Beninato, L. Mazzeo, C.G. Rea, G. Mariani, F. de Braud, G.V. Bianchi, C. Vernieri, G. Capri